The Merit of Tyrosine Kinase inhibitors in the adjuvant setting of high-risk renal cell carcinoma Ameta-Analysis
LMJ-Lebanese Medical Journal. 2019; 67 (suppl.): 39-42
in English, French
| IMEMR
| ID: emr-206753
ABSTRACT
Background:
Loco-regional renal cell carcinoma [RCC] accounts for 15 to 20 percent of patients with RCC, with a risk of post-surgical relapse of 40 percent [1,2]. Following the adoption of tyrosine kinase inhibitors [TKIs] as the first-line treatment of metastatic RCC, multiple studies evaluated Sunitinib [3,4] and Pazopanib [5] in the adjuvant setting of high-risk resected RCC. However, these studies have yielded inconclusive results, and there are currently no meta-analyses combining the results of all trials evaluating TKIs in the adjuvant setting of high-risk RCC. The aim was to perform a meta-analysis to evaluate and compare the possible benefit of Sunitinib and Pazopanib on diseasefree survival [DFS] in the adjuvant setting of high-risk RCC
Search on Google
Index:
IMEMR (Eastern Mediterranean)
Type of study:
Controlled clinical trial
Language:
English
/
French
Journal:
Lebanese Med. J.
Year:
2019
Similar
MEDLINE
...
LILACS
LIS